The presence of cardiovascular comorbidity in non-small-cell lung cancer (NSCLC) patients increases with age. Therefore, the influence of cardiovascular comorbidity in NSCLC patients on their short-or long-term prognosis remains controversial. This study evaluated the possible risk factors related to the short-term and long-term survivals in NSCLC patients with cardiovascular comorbidity.
BACKGROUND
Lung cancer is the leading cause of cancer-related death in many countries, and approximately 1.6 million new cases a year are estimated worldwide [1] . Therefore, the number of elderly lung cancer patients is increasing rapidly worldwide. The Japanese Cancer Surveillance Research Group reported that as many as 65% of lung cancers were diagnosed in patients older than 70 years of age and 25% in those older than 80 years [2] . The increasing mean age of the population will therefore increase the number of patients diagnosed with one or more other serious diseases at the time of lung cancer diagnosis [3] . In fact, the presence of cardiovascular comorbidity in non-smallcell lung cancer (NSCLC) patients increases with age [3, 4] . The incidence of cardiovascular comorbidity in patients with NSCLC is reported to be between 13 and 49% [3] [4] [5] [6] [7] [8] [9] [10] . On the other hand, the influence of cardiovascular comorbidity in NSCLC patients on their short-or long-term prognosis remains controversial [4] [5] [6] [7] [8] [9] [10] [11] .
The aim of this study was to evaluate the possible risk factors related to the short-and long-term survivals in NSCLC patients with cardiovascular comorbidity.
MATERIALS AND METHODS

Patients and methods
One thousand one hundred and sixty-two consecutive patients with NSCLC who underwent surgical resections at the Kyushu Medical Center between 1984 and 2010 were analysed in this study. The eligibility criteria for a patient undergoing surgery in this hospital were essentially: (i) C-Stage IA to IIIA disease; (ii) performance status 0-2; (iii) a calculated postoperative forced expiratory volume in 1 second (FEV1) ≥0.6 l/m 2 ; (iv) being without major risk factors for cardiac complications during the perioperative period of non-cardiac surgery according to the Japanese Circulation Society [12] ; (v) written or oral informed consent obtained from patients. Our surgical policy regarding lung cancer patients favours radical resection such as lobectomy and pneumonectomy with mediastinal lymph node dissection. On the other hand, some of the patients underwent limited resection from the aspects of pulmonary function or oncological behaviour.
Perioperative examination
Clinical staging was based on computed tomography (CT) of the chest and upper abdomen, brain CT or magnetic resonance imaging, radionuclide bone scan and/or positron emission tomography with fluorine-18 fluorodeoxyglucose. Mediastinoscopy and endobronchial ultrasound mediastinal lymph nodes biopsies were performed as needed. Routine preoperative assessments included medical history, physical examination, basic blood tests, electrocardiogram (ECG), echocardiography, carotid ultrasonography, pulmonary function test and blood gas examination. All patients with cardiovascular disease, suspicious symptoms or ECG abnormalities in an exercise stress test consulted a cardiologist and underwent additional tests, such as coronary CT, thallium-dipyridamole myocardial scintigraphy, or coronary angiography was performed. The histological diagnosis of the tumours was based on the criteria of the World Health Organization [13] , and the TNM stage was determined according to the revised criteria [14] .
Preoperative condition of cardiovascular comorbidities
Hypertension is defined as a repeatedly elevated blood pressure with a systolic pressure >140 mmHg or with a diastolic pressure >90 mmHg. Almost all patients had been diagnosed with hypertension and they had also been preoperatively controlled with medication. The patients with coronary artery disease included those who had undergone revascularization procedures such as percutaneous coronary interventions or coronary artery bypass grafting and those on medication who were diagnosed with coronary artery disease. Any patients with unstable coronary diseases, such as myocardial infarction occurring 30 days before thoracic surgery, unstable angina and severe angina, such as Canadian Cardiovascular Society Angina Grading Scale III or IV, were considered to not be indicated for lung resection. The peripheral artery disease included arteriosclerosis obliterans of the lower extremities and carotid artery stenosis. In addition, symptomatic patients with 70% or more stenosis of the carotid artery were essentially treated with carotid endarterectomy or carotid endovascular treatment prior to lung resection, while the other cases were basically treated with medication.
The arrhythmia group of patients included those diagnosed with arrhythmia and who were treated with either medication or with implantable pacemakers. The most common arrhythmia was atrial fibrillation, while the other types included premature ventricular contractions, premature atrial contraction, sick sinus syndrome and atrioventricular block. The patients with abdominal aortic aneurysm included cases that were asymptomatic and had aneurysms measuring <6 cm in diameter. The cases that were symptomatic or had aneurysms measuring 6 cm or more in diameter were considered to be indicated for treatment prior to lung resection. The patients who did not meet our standards for lung resection due to cardiovascular comorbidities received treatment for the cardiovascular disease prior to the surgery, and the possibility of curative lung resection was reconsidered if their condition improved.
Data collection and extraction
Demographic, clinical, surgical, anaesthetic data and perioperative complications were abstracted from an institutional database that included all patients who had undergone thoracic surgery. Written informed consent was obtained from each patient to use their medical records. The institutional review board gave its approval for this study.
Statistical analysis
The relationships among the clinicopathological factors and cardiovascular comorbidity were analysed using the χ 2 -test. The probability of survival was estimated using the Kaplan-Meier method. Differences in survival were evaluated by means of the log-rank test. The data were considered to be significant when the P-value was <0.05.
RESULTS
Patients
The age of the patients ranged from 20 to 88 years (mean 67), including 762 males and 392 females (Table 1) . Adenocarcinoma accounted for 62% (n = 712), followed by squamous cell carcinoma (n = 309, 27%) and other histological types (n = 133, 11%). (Table 1) . Eighty-three patients exhibited more than one type of comorbidity. The distribution of cardiovascular comorbidity according to age is shown in Figure 1 . Cardiovascular comorbidity in NSCLC patients increased progressively with age. Remarkably, more than half of the patients aged 80 years or older had cardiovascular comorbidity (Fig. 1) . The types of procedures performed included minimal surgery such as wedge resection or segmentectomy (n = 221), lobectomy (n = 904) and pneumonectomy (n = 37; Table 2 ). The overall rate of postoperative cardiac complications was 3.4%, pulmonary complications 18% and surgical mortality 0.9% (Table 3 ). Table 3 shows that the most common postoperative cardiac complications were arrhythmias (3%). There was no association between postoperative adverse events and preoperative cardiovascular comorbidity. The surgical mortality rate of the patients with cardiovascular comorbidities was 1%, and the causes of mortality were cardiac failure (n = 1), cardiac arrhythmia (n = 1), bronchopleural fistula (n = 1) and thrombosis of the superior mesenteric artery (n = 1). The mortality rate of the patients without cardiovascular comorbidities was 0.8%, and the causes of mortality were pneumonia (n = 3), cardiac failure (n = 1), cardiac arrhythmia (n = 1) and pulmonary embolism (n = 1). There was no correlation between mortality and preoperative cardiovascular comorbidity. The 5-year survival rates of the patients with cardiovascular comorbidity were 62.5% in comparison with 64.5% among patients without cardiovascular comorbidity (P = 0.48; Fig. 2 ).
DISCUSSION
Although surgery offers the best chance of a cure for early stage NSCLC, postoperative morbidity and mortality after surgical resection of NSCLC continue to be a major concern for thoracic surgeons. Improving the surgical outcome requires knowledge of the risk factors prior to surgery and that of postoperative mortality and morbidity. Generally, postoperative complications are reported to be associated with preoperative comorbidities [11, 15, 16] . The incidence of cardiovascular comorbidity in NSCLC patients increases with age [3, 4] . In addition, cigarette smoking is highly associated with the development of lung cancer; therefore, cardiovascular disease is regarded as having a strong association with lung cancer, with the same etiological factor as tobacco. However, the influence in surgical NSCLC patients on their short-or long-term outcome is controversial [4] [5] [6] [7] [8] [9] [10] [11] . Licker et al. [5] reported that American Society for Anesthesiologists (ASA) classes 3 and 4, and coronary artery disease, are independent risk factors of operative death for NSCLC. Similarly, Ambrogi et al. [7] reported that cardiovascular disease has a negative effect on survival and mortality in patients who undergo surgery for Stages I and II NSCLC. On the other hand, Figure 1 : Preoperative cardiovascular comorbidity in NSCLC patients separated by age. The presence of cardiovascular comorbidity in NSCLC patients increases with age. several authors reported that cardiac comorbidity is not a risk or has little risk for mortality and morbidity following surgery for primary NSCLC [9] [10] [11] . This institute evaluates cardiovascular comorbidities before surgery, therefore, the indications for surgery among patients with cardiovascular comorbidity are based on the guidelines of the Japanese Circulation Society [12] . Patients who do not satisfy the conditions of these guidelines receive treatment other than surgery in principle. Patients with cardiovascular comorbidity who are taking antithrombotic medicines or anticoagulants must discontinue these medications and receive heparin preoperatively. All patients receive heparin shortly after surgery, and then they continue antithrombotic medications or anticoagulants when they can take oral medications. The total morbidity and mortality rates after pulmonary resection in this institute were 25 and 0.9%, respectively. The database published by the Society for Thoracic Surgeons revealed that the mortality rate is 2.5% after pulmonary resection [16] . The Japanese Joint Committee of Lung Cancer Registry ( JJLCR) has regularly conducted nationwide registrations of lung cancer for every 5 years [17, 18] . The rate of severe postoperative complications is 4.5%, the percentage of operative deaths is 0.4% and that of hospital deaths is 0.4% in the 2004 registry [17] . The postoperative outcome of this institute is comparable with these results. On the other hand, cardiovascular comorbidity is a risk factor for early mortality and major complications in cases with high-risk procedures such as pneumonectomy or sleeve lobectomy [6, 8] . Perioperative management should be cautiously performed, if extended lung resections are needed to achieve a cure.
There are a number of limitations associated with this study. One of the limitations is the retrospective setting of this study. Secondly, although the surgical policy is to perform radical surgery, the final decision to perform surgical procedures may be based on the common understanding of the surgeons and the patients; therefore, standard procedures were not selected in some cases. In fact, significantly more limited resections were performed for the patients with cardiovascular comorbidity than for those without cardiovascular comorbidity. However, the long-term outcome was not significantly different between those with and without cardiovascular comorbidity. Therefore, it might be correct to select a more suitable procedure based on the patients' overall condition rather than their lung cancer conditions. Despite these limitations, this study evaluated the influence of cardiovascular comorbidity in over 1000 NSCLC cases; therefore, these results reflect the actual clinical outcome of surgical resection for NSCLC in Japan.
In conclusion, patients with cardiovascular comorbidity are not found to be at an increased risk of mortality and cardiac morbidity following surgery for NSCLC if appropriate selection and care of those patients are addressed. In addition, cardiovascular comorbidity did not influence the long-term outcomes of patients after a pulmonary resection for NSCLC.
Conflict of interest: none declared. We read the article by Takenaka et al. with great interest [1] . The authors concluded that patients with cardiovascular comorbidity did not have increased risk of mortality and morbidity following surgery for non-small cell lung cancer (NSCLC), and cardiovascular comorbidity did not influence the long-term outcomes of patients after a pulmonary resection for NSCLC.
Due to an aging population and increasing cancer rates, it is anticipated that an increasing number of older patients will be to be referred to physicians and surgeons with an NSCLC diagnosis in the coming years. Old age and other cardiovascular risk factors are often the cause of death in these patients. As the treatment for cancer improves and deaths from other factors decrease, only cancer-related mortality rates seem to increase. When higher life expectancy rates and new treatment modalities are made available to this increasing body of elderly population, it will be real progress if patients are not left to die from old age or advanced cancer. In fact, the prognosis of patients with NSCLC has improved lately, possibly due to the standardization of methods like adjuvant chemotherapy and the advent of molecular-targeted therapies, notably epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors and other new anti-cancer agents [2] . As these older patients provide a group with higher cardiovascular risks, the present study is very important in terms of assessing these risks in patients with NSCLC, although it has been made retrospectively. As a matter of fact, a previous study reported that older age is not a contraindication to lung surgery for NSCLC and operative mortality has improved over the years [3] . They stated that surgery could be performed as a safe and justifiable option for older patients. However, it was mentioned that patient selection and a careful preoperative work-up are obligatory to get good results and physicians should be careful when evaluating the patient's current cardiovascular and respiratory comorbidities [3] . Good long-term results in elderly patients could be achieved if these factors were carefully considered [3] . In recent years, videoassisted thoracoscopic surgery (VATS) has been a less invasive method in the diagnosis and treatment of patients with NSCLC in selected patients [4] . We think that this method should be considered in patients with real indications. If they are older and have higher cardiovascular risks, VATS, at least in part, may be an alternative option for the diagnosis and treatment of these patients. Another issue is that diabetes is a cardiovascular risk equivalent and the study would be stronger if the diabetic status of the patients were also mentioned.
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